Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.64 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20886132 | 1.00 | STING1 (0.64) | STING1TBK1 | |
| SCHEMBL20066454 | 0.93 | STING1 (0.67) | STING1TBK1 | |
| SCHEMBL19451766 | 0.93 | STING1 (0.66) | STING1TBK1 | |
| SCHEMBL19451601 | 0.92 | STING1 (0.62) | STING1TBK1 | |
| SCHEMBL29626038 | 0.92 | STING1 (0.62) | STING1TBK1 | |
| Formic Acid SCHEMBL29626075 | 0.91 | STING1 (0.64) | STING1TBK1 | |
| SCHEMBL19451708 | 0.91 | STING1 (0.68) | STING1TBK1 | |
| SCHEMBL19451616 | 0.91 | STING1 (0.68) | STING1TBK1 | |
| SCHEMBL19451741 | 0.90 | STING1 (0.66) | STING1TBK1 | |
| Trifluoroacetic Acid SCHEMBL29619920 | 0.89 | STING1 (0.62) | STING1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | claimed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-12178851-B2 | Methods for administering STING agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | STING1 1/4885TBK1 8/4885 |
| US-12178851-B2 | Methods for administering STING agonists | STING1, CGAS, TLR9 | STING1 1/4885TBK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.